- A recent clinical trial used Psygen’s patent-pending synthetic formula.
- The Company believes that Psygen’s patent-pending technology will improve yields and margins on revenue, and that the technology is key to scale-up and automation.
Psygen Industries Ltd. provided an update today on its intellectual property portfolio and on use of psilocybin in humans. Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured using Psygen’s patent-pending synthetic method. The Company believes that Psygen’s patent-pending technology will improve yields and margins on revenue, and that the technology is key to scale-up and automation.
Psygen has developed key intellectual property rights focused on optimized manufacturing processes for psilocybin and other tryptamines. In 2021, Psygen filed two provisional patent applications at the United States Patent and Trademark Office, establishing priority dates. Current data on one of the two technologies shows evidence of improved efficiency and economics in the manufacture of psilocybin and other tryptamines. A second patent-pending technology developed by Psygen may provide additional formulation options for psilocybin.
Psygen has also developed key manufacturing and analytical processes that will be applied to manufacture and release of the pharmaceutical quality Active Pharmaceutical Ingredients (“APIs“), both for controlled substances and unscheduled substances that will be offered by Psygen. These processes are expected to be applied at Psygen’s facility once construction is completed, and in the case of controlled substances, once Psygen’s application for a dealer’s licence has been issued.
“Psygen was founded to improve access to psychedelic medicines for therapeutic applications and for research. Our work is focused on scaling production processes for synthetic psychedelic drugs. Any time a process is optimized, that optimization might be patentable. Psygen will create unique, comprehensive methods that render the ultimate process more efficacious.”Danny Motyka, CEO of Psygen
In addition to establishing priority dates for the protection of Psygen’s recent innovations by filing provisional patent applications, Psygen has protected its brand through filing applications for registration of trademarks.
Psygen intends to be a leading provider of psychedelics for healing and wellness. Psygen will be a manufacturer of pharmaceutical-grade psychedelic drug substances for clinical research and therapeutic applications. Psygen consists of a team of industry and business experts with over 25 years of direct experience in manufacturing psychedelics. Psygen is building Canada’s first dedicated psychedelics manufacturing facility for the synthesis of psychedelic drugs for clinical research and approved therapeutic applications. Psygen has worked in partnership with an existing Licensed Dealer to develop manufacturing protocols for psychedelic drug products.